Recent studies demonstrated that
Chemokines are members of a family of small, secreted proteins that are potent activators and chemoattractants for leukocyte subpopulations. Chemokines act as ligands for a family of seven-transmembrane-spanning G-protein-coupled receptors (1, 2) . Chemokine receptor expression on different cell types and their binding and response to specific chemokines are highly variable (2) . By virtue of this diversity, chemokines can direct the selective migration of lymphocyte subsets from intravascular to extravascular compartments, trafficking of lymphocyte subsets within lymph node and thymus and/or recirculation of lymphocytes from tissues to lymphatics (3) .
Recent studies have started to investigate the expression of chemokines and chemokine receptors in Hodgkin's disease (HD) and non-Hodgkin lymphomas (NHL; 4 -6) . Chemokines are considered to play an important role both in the selective homing of neoplastic B and T cells, which may contribute to the preferential localization of some types of lymphomas at certain sites, and in the recruitment of inflammatory cells, which may modulate antitumor responses. In a recent study, Van den Berg et al. (7) reported expression of the chemokine TARC (thymus and activation-regulated chemokine) by ReedSternberg cells in all cases of mixed cellularity (mc) and nodular sclerosing (ns) Hodgkin's disease. TARC is considered to play a role in T-cell develop-ment in the thymus and in trafficking and activation of mature T cells (8) . TARC-positive ReedSternberg cells were surrounded by T cells expressing CC-chemokine receptor 4 (CCR4), one of the receptors of TARC, suggesting that TARC production by Hodgkin/Reed-Sternberg (H/RS) cells could play a role in the influx of reactive T-lymphocyte subsets (7) . Because CCR4 is preferentially expressed by Th2-polarized T cells expressing IL-4, IL-5, and IL-10 (9, 10), it was postulated that the preferential attraction of CCR4-bearing Th2 lymphocytes may cause a shift towards a Th2-dominated cytokine microenvironment, thereby hampering the cytotoxic immune response and providing a mechanism by which neoplastic cells are able to escape from the immune system. Whether such a mechanism might also be operative in CD30-positive malignant lymphomas other than HD is as yet unknown, because data on the expression of TARC and CCR4 in these conditions are scarce.
In the present study, we therefore investigated expression patterns of TARC and CCR4 in a large group of 64 CD30-positive NHL, including ALKpositive and ALK-negative nodal anaplastic large cell lymphomas (ALCL), CD30-positive primary cutaneous ALCL, and lymphomatoid papulosis (LyP); in addition, 31 cases of HD were investigated.
MATERIALS AND METHODS

Patients
Paraffin-embedded material of the following lymphoma types, classified according to the World Health Organization (WHO) criteria (11), were retrieved from the archives of the Department of Pathology of the Vrije Universiteit Medical Center, Amsterdam, the Netherlands: nsHD (n ϭ 18), mcHD (n ϭ 6), and lymphocyte predominant (lp) HD (n ϭ 7) and nodal ALCL (n ϭ 39), including 12 ALK-positive and 27 ALK-negative ALCL, as assessed by staining with monoclonal antibody ALK-1 (12, 13) . Frozen material of these lymphomas was available in 8 cases of nsHD and in 19 nodal ALCL.
Primary cutaneous lymphomas were classified according to the WHO criteria and also according to the classification of primary cutaneous lymphomas of the European Organization for the Research and Treatment of Cancer (11, 14) and included 11 primary cutaneous CD30-positive ALCL and 15 cases of lymphomatoid papulosis (LyP). Frozen material was available of 5 primary cutaneous ALCL and 4 cases of LyP.
All cases were reviewed by an expert hematopathologist (CJLMM) and dermatologist (RW). Furthermore, all lymphoma diagnoses were confirmed by a panel of expert hematopathologists from the Comprehensive Cancer Center Amsterdam. Tonsil (n ϭ 2), hyperplastic lymph nodes (n ϭ 2), thymus (n ϭ 4), and skin biopsies from lichen planus (n ϭ 4) were included as positive control for the expression of CCR4 and TARC, as described elsewhere(3).
Immunohistochemistry
Lymphoma Phenotyping
Lymphomas were extensively immunophenotyped using monoclonal antibodies against CD3, CD4, CD8, CD45RO, CD15, CD20, CD23 and TIA-1, GrB, CD30, and ALK-1, as described elsewhere (15, 16) . In all cases of classical HD, the neoplastic H/RS cells stained with the CD30 antibody. Expression of CD15 was detected in 17/24 cases, and a variable number of neoplastic cells stained positive for CD20 in 6/24 cases. No expression of T-cell markers was found. The tumor cells in all lpHD cases (n ϭ 7) were negative for CD30, CD15, and T-cell-associated antigens but were positive for CD20, as expected. The presence of Epstein-Barr virus was detected in 8/24 cases of classical HD by EBER1/2 RNA in situ hybridization and LMP1 immunohistochemistry (17) .
All cases of ALCL (n ϭ 39) were subclassified according to the WHO classification (11) . All ALCL showed expression of CD30; EMA was observed in 14/39 cases, and the majority of ALCL expressed T-cell markers (21/27). Expression of B-cell markers CD20 and CD79a was not observed (Table 1) .
In primary cutaneous CD30-positive ALCL, expression of CD30 was found in Ն75% of the tumor cells. In nearly all cases, the neoplastic cells showed a CD3
ϩ /CD4 ϩ /CD8 Ϫ phenotype. The great majority of neoplastic T-cells in LyP expressed CD3, CD4, and CD30; CD8 was never detected.
TARC Detection
Paraffin sections were incubated with TARC polyclonal antibody 1:200 (goat-anti-TARC; R&D Systems, Minneapolis, MN) followed by biotinylated rabbit anti-goat IgG (1:250; Vector, Burlingame, CA). TARC detection on frozen tissues was performed using a mouse monoclonal antibody (moab) 2D8 1:1000 (Leukosite Inc., Boston, MA) and biotinylated rabbit anti-mouse antibodies. In both frozen and paraffinembedded material, the biotinylated antibodies were detected with horseradish peroxidase-conjugated streptavidin-biotin complex (sABC, DAKO, Glostrup, Denmark) and visualized with diaminobenzidine (3,3'-diaminobenzidine).
Tumors were considered positive if Ͼ5% of tumor cells stained for TARC.
CCR4 Detection
Immunohistochemical detection of CCR4 was performed on frozen material using mouse moab 1G1 1:100 (Leukosite Inc.). Visualization of the primary antibody was performed using a standard three-step sABC method and 3,3'-diaminobenzidine.
Tumors were considered positive if Ͼ5% of tumor cells stained for CCR4.
Double Staining
Double staining of TARC and CCR4 was performed to illustrate the topographical distribution of CCR4-positive infiltrating cells in relation to TARC-expressing neoplastic cells. Goat anti-TARC and 1G1 were applied simultaneously, followed by simultaneous incubation of biotinylated donkey anti-goat and rabbit anti-mouse antibody. Subsequently, biotin was detected by sABC, whereas a double alkaline phosphatase anti-alkaline phosphatase was used to detect CCR4. TARC was visualized by 3,3'-diaminobenzidine and CCR4 by new fuchsin.
RESULTS
Hodgkin's Disease
TARC expression was found in paraffin sections of all cases of nsHD (n ϭ 18) and mcHD (n ϭ 6), showing a strong cytoplasmic staining in the neoplastic H/RS cells (Fig. 1, Table 2 ). Virtually all H/RS cells showed expression of TARC, whereas no expression was found in small or intermediate-sized cells in the reactive infiltrate. Expression of TARC was also detected in 3/7 cases (43%) of lpHD. In eight cases of nsHD from which frozen material was available, an identical staining pattern for TARC was observed ( Fig. 2A) . Evaluation of CCR4 expression in these sections showed that H/RS cells were negative for CCR4 in all cases (Tables 2 and 3 and Fig. 2B ).
Expression of TARC was also detected on dendritic cells and on endothelial cells, especially in high endothelial venules. Staining for CCR4 was detected as a membranous staining on small numbers (Ͻ5%) of reactive T cells in 5 of 8 cases and on higher numbers (10 -15%), mainly surrounding the H/RS cells, in 3 of 8 cases. This was confirmed by immunohistochemical double staining as depicted in Figure 2C .
Nodal ALCL
Paraffin sections of 39 cases of ALCL were investigated for the expression of TARC. In 12/39 (31%) 
ND, not determined; cyt phenotype; cytotoxic phenotype of the tumor cells.
a B-cell phenotype as determined by expression of CD20 and/or CD79a.
b T-cell phenotype as determined by expression of CD3, CD4, CD8, and CD45. cases a clear, dotlike, cytoplasmic staining was observed in the neoplastic cells (Fig. 3) In all TARCpositive cases, Ͼ90% of the tumor cells stained positive. TARC expression was observed in the neoplastic T cells of 12/27 (44%) ALK-negative nodal ALCL, but not in any of the 12 ALK-positive cases. Similarly, on frozen tissue, 9/15 (60%) ALK-negative ALCL, but 0/4 ALK-positive ALCL, expressed TARC (see Table 2 ). The expression of TARC by the neoplastic cells on frozen tissue was identical to paraffin sections in all cases.
Expression of CCR4 by the large anaplastic cells was found in 9/15 (60%) ALK-negative ALCL and 1/4 (25%) ALK-positive ALCL (see Tables 2 and 3) . Coexpression of TARC and CCR4 was found in 5/15 (33%) ALK-negative ALCL.
Expression of TARC was also detected on high endothelial venules in all cases. Stainings for CCR4 demonstrated that CCR4 was expressed by a small minority (Ͻ5%) of reactive T cells in all cases of nodal ALCL (see Table 2 ).
Primary Cutaneous CD30-Positive Lymphomas
Staining of paraffin sections showed TARC expression by a minority of the neoplastic CD30-positive cells in 1/11 cases of primary cutaneous ALCL and 2/15 cases of LyP. Expression of CCR4 by neoplastic cells was observed in 5/5 primary cutaneous ALCL and in 4/4 of LyP. In all cases, a small minority (Ͻ5%) of reactive lymphocytes expressed CCR4 (Table 2) .
Control Tissue
In thymus, TARC was detected as a strong cytoplasmic staining in cells with a dendritic morphology residing in the medulla. In tonsils and inflamed lymph nodes, expression of TARC was found in high endothelial venules. Endothelial cells in lichen planus did, however, not express TARC. Expression of CCR4 was found on 10 -20% of reactive T lymphocytes and by dendritic cells in the dermis in skin biopsies from lichen planus, as described elsewhere (3).
DISCUSSION
In this study, major differences in the expression of the CC-chemokine TARC and its ligand CCR4 were demonstrated in different types of CD30ϩ lymphomas. TARC was expressed by the neoplastic cells in 27 of 31 cases of HD, including 18/18 nsHD, 6/6 mcHD, and 3/7 lpHD; and in 12/27 CD30ϩ ALK-negative ALCL but not in CD30ϩ ALK-positive ALCL; and in only 3/27 primary cutaneous CD30ϩ lymphoproliferative disorders, including 1/11 primary cutaneous CD30-positive ALCL and 2/15 cases of LyP.
The consistent expression of TARC by H/R-S cells in cases of mcHD and nsHD is in accordance with the results of previous studies (7) . In contrast to Van den Berg et al. (7) , TARC expression was also found in 3/7 cases of lpHD. These findings suggest that TARC expression is a constant feature of HD. However, the expression of TARC in approximately half of the cases of nodal ALK-negative ALCL indicates that TARC expression is not specific for HD, and thus cannot be used as a diagnostic criterion in the differential diagnosis between HD and ALCL.
The differential expression of TARC between ALK-negative (12/27, 44%) and ALK-positive (0/12) nodal ALCL is a new finding providing yet another biological difference between these two subtypes of ALCL. Earlier studies of TARC expression in ALCL are limited to one recent study in which expression of TARC was not found on three ALK-negative ALCL, whereas ALK-positive ALCL were not investigated (7) . In addition, we found that TARC expression was not specific for CD30-positive lymphomas because in a minority of CD30-negative lymphomas, of either nodal or cutaneous origin, TARC expression was detected in the neoplastic cells (1/11 follicular lymphomas, 1/12 diffuse large B-cell lymphomas (DLBCL), 1/2 cutaneous DLBCL, and Cases were considered positive if Ͼ5% of the tumor cells expressed TARC or CCR4. ALCL, anaplastic large cell lymphoma; ns, nodular sclerosing; mc, mixed cellularity; lp, lymphocyte predominant; ND, not determined.
3/11 T-NHL not otherwise specified [data not shown]).
In contrast, CCR4 was expressed most strikingly and consistently by the neoplastic cells in primary cutaneous CD30ϩ lymphoproliferative disorders (9/9) and to a lesser extent by CD30ϩ ALK-negative ALCL (9/15, 60%), but not by HD and in only one case of ALK-positive ALCL. The expression of CCR4 on neoplastic cells in half of the cases of ALKnegative ALCL is in line with the study by Jones et al. (18) who demonstrated CCR4 expression in 3/6 ALK-negative ALCL. In contrast to our study, expression of CCR4 was found in all cases of ALKpositive ALCL (5/5; 18) . This difference observed in the expression of CCR4 by ALK-positive ALCL is as yet unexplained.
The expression of CCR4 in all cases of cutaneous ALCL and LyP is consistent with the hypothesis that CTCL are characterized by a Th2-like cytokine profile (19, 20) . With respect to cutaneous CD30ϩ lymphoproliferations, one study indeed showed increased expression of Th2 cytokines by transcription analysis (21). a Cutaneous CD30ϩ ALCL (n ϭ 5) and lymphomatoid papulosis (n ϭ 4), as found in double stainings.
TARC, thymus and activation-regulated cytokine; HD, Hodgkin's disease; ns, nodular sclerosing; ALCL, anaplastic large-cell lymphoma; NHL, non-Hodgkin's lymphoma.
Examination of serial sections and double-staining experiments indicate a TARCϩ/CCR4Ϫ phenotype in all cases of nsHD, a TARCϪ/CCR4ϩ phenotype in all cases of primary cutaneous CD30ϩ lymphoproliferative disorders, and a TARCϪ/CCR4Ϫ phenotype in 3/4 ALK-positive ALCL, whereas the phenotype of ALK-negative ALCL showed considerable variation (see Table 3 ).
Previous studies demonstrated TARC expression by H/RS cells in nsHD and mcHD and CCR4 expression by reactive T cells surrounding these TARC-positive H/RS cells. Because CCR4 is preferentially expressed by Th2-cells expressing IL-4, IL-5, and IL-10 (9, 10), it was postulated that production of TARC by H/RS cells may play a role in the evasion of the antitumor immune response in HD (22) . In the present study, the expression of TARC by H/RS cells was confirmed. However, in contrast to the results of Van den Berg et al. (7) , considerable numbers of CCR4ϩ reactive T lymphocytes surrounding the H/RS cells were only found in 3/8 cases, whereas in the other 5 cases, very few CCR4ϩ T lymphocytes were found. This difference in the expression of CCR4 may be explained by differences in the techniques used to detect CCR4. We used immunohistochemistry to detect CCR4 at the protein level, whereas Van den Berg et al. (7) used in situ hybridization to detect CCR4 mRNA, indicating either posttranscriptional modification of CCR4 mRNA or alternatively, a less sensitive immunohistochemical method to detect CCR4 protein. However, staining for CCR4 observed in neoplastic cells in nodal ALCL, and reactive T lymphocytes in skin biopsies of lichen planus is in accordance with earlier studies (3) and argues against this latter possibility. Not only in most cases of nsHD, but also in all nodal and cutaneous CD30-positive lymphomas, only few scattered CCR4ϩ reactive T cells were observed. This observation argues against an important role for TARC in modulating the cytokine microenvironment by attracting CCR4-positive T lymphocytes. Nevertheless, the presence of considerable proportions of CCR4-positive reactive lymphocytes, often in close vicinity of H/RS cells in 3/8 cases of nsHD, may suggest that evasion of the antitumor immune response by production of TARC might still be a mechanism operative in a minority of HD cases.
In addition to their potential role in modulating antitumor responses by recruitment of different types of inflammatory cells, chemokines are considered to play an important role in the selective homing and dissemination of both normal and malignant B and T cells (23, 24) . Earlier studies demonstrating expression of TARC by endothelial cells in inflamed skin and expression of CCR4 by skinhoming (CLAϩ) T cells suggest that TARC and CCR4 are important in the homing of T cells to the skin (3) . The expression of CCR4 by neoplastic cells in all primary cutaneous CD30ϩ lymphomas and absence of CCR4 expression in HD is in line with this hypothesis. However, expression of CCR4 by neoplastic cells was also detected on 10/15 (67%) of nodal CD30ϩ ALCL. In all nodal lymphomas, a proportion of endothelial cells, especially in high endothelial venules, expressed TARC, whereas the endothelial cells in primary cutaneous CD30ϩ ALCL were consistently negative. Thus, our results do not support an important role for TARC-CCR4 interactions in the preferential homing of these primary cutaneous CD30ϩ ALCL in the skin.
In conclusion, we show that TARC expression is not specific for HD, but can also be found in half of the cases of nodal ALK-negative ALCL, but not in ALK-positive ALCL and only rarely in primary cutaneous ALCL. However, because expression of TARC is generally not associated with a considerable infiltration of CCR4-positive reactive T cells, the biologic significance of this differential expression requires further study. The expression of CCR4 by neoplastic cells of primary cutaneous CD30ϩ lymphoproliferative disorders and of 60% of nodal ALKnegative ALCL, in addition to the weak expression or even absence of TARC-positive endothelial cells in these lymphomas, does not support an important role in the spreading of these lymphomas.
